Literature DB >> 15990899

Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors.

Mervi Laakso1, Niklas Loman, Ake Borg, Jorma Isola.   

Abstract

Breast ducts contain two types of epithelial cells, inner luminal cells and outer basal/myoepithelial cells. These cells can be distinguished by their immunophenotype. Cytokeratins (CKs) 8 and 18 are expressed in the luminal layer, whereas CK5/14 and the transcription factor p63 characterize the basal epithelial layer. We studied a population-based cohort of 288 sporadic ductal invasive cancers and found 9% positive for CK5/14 and 4% positive for p63. Using a highly sensitive polymer-based immunohistochemical staining, all sporadic tumors were positive for the luminal CK8/18, including those positive for CK5/14. Pairs of primary tumors and metastases (n = 38) were always concordant for CK5/14 expression. The majority of the CK5/14-positive cases were of histologic grade III (P = 0.0007) and steroid hormone receptor negative (P < 0.0001). CK5/14 expression was inversely associated with HER-2 oncogene amplification, but only in the subgroup of estrogen receptor-negative tumors (P = 0.007). In a separate set of 42 hereditary breast cancers, the majority (78%) of the BRCA1-associated tumors, but only one of 15 BRCA2-associated tumors was positive for CK5/14. In contrast to sporadic CK5/14-positive tumors, BRCA1-associated tumors displayed less intense CK8/18 staining, including some truly CK5/14-positive CK8/18-negative cases. These results suggest that CK5/14-positive sporadic breast cancers arise from glandularly committed progenitor cells rather than true CK8/18-negative basal cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15990899     DOI: 10.1038/modpathol.3800456

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  49 in total

1.  Electrospun fibrous scaffolds promote breast cancer cell alignment and epithelial-mesenchymal transition.

Authors:  Sharmistha Saha; Xinrui Duan; Laying Wu; Pang-Kuo Lo; Hexin Chen; Qian Wang
Journal:  Langmuir       Date:  2011-12-27       Impact factor: 3.882

2.  CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registry.

Authors:  Anna Marie Mulligan; Dushanthi Pinnaduwage; Anita L Bane; Shelley B Bull; Frances P O'Malley; Irene L Andrulis
Journal:  Cancer       Date:  2010-11-02       Impact factor: 6.860

3.  Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component.

Authors:  Patrick E Corsino; Bradley J Davis; Peter H Nørgaard; Nicole N Teoh Parker; Mary Law; William Dunn; Brian K Law
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

4.  Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Authors:  Begoña Martin-Castillo; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Silvia Cufí; José Manuel Moreno; Bruna Corominas-Faja; Ander Urruticoechea; Ángel G Martín; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

Review 5.  Understanding and treating triple-negative breast cancer.

Authors:  Carey Anders; Lisa A Carey
Journal:  Oncology (Williston Park)       Date:  2008-10       Impact factor: 2.990

6.  Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.

Authors:  Nadine Tung; Yihong Wang; Laura C Collins; Jennifer Kaplan; Hailun Li; Rebecca Gelman; Amy H Comander; Bridget Gallagher; Katharina Fetten; Karen Krag; Kathryn A Stoeckert; Robert D Legare; Dennis Sgroi; Paula D Ryan; Judy E Garber; Stuart J Schnitt
Journal:  Breast Cancer Res       Date:  2010-02-11       Impact factor: 6.466

7.  Identification, expansion and characterization of cancer cells with stem cell properties from head and neck squamous cell carcinomas.

Authors:  Hatem O Kaseb; Helene Fohrer-Ting; Dale W Lewis; Eric Lagasse; Susanne M Gollin
Journal:  Exp Cell Res       Date:  2016-09-09       Impact factor: 3.905

8.  Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.

Authors:  Lao H Saal; Sofia K Gruvberger-Saal; Camilla Persson; Kristina Lövgren; Mervi Jumppanen; Johan Staaf; Göran Jönsson; Maira M Pires; Matthew Maurer; Karolina Holm; Susan Koujak; Shivakumar Subramaniyam; Johan Vallon-Christersson; Håkan Olsson; Tao Su; Lorenzo Memeo; Thomas Ludwig; Stephen P Ethier; Morten Krogh; Matthias Szabolcs; Vundavalli V V S Murty; Jorma Isola; Hanina Hibshoosh; Ramon Parsons; Ake Borg
Journal:  Nat Genet       Date:  2007-12-09       Impact factor: 38.330

9.  Does vimentin help to delineate the so-called 'basal type breast cancer'?

Authors:  Renata U Kusinska; Radzislaw Kordek; Elzbieta Pluciennik; Andrzej K Bednarek; Janusz H Piekarski; Piotr Potemski
Journal:  J Exp Clin Cancer Res       Date:  2009-08-20

10.  BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression.

Authors:  M Yan; M Rayoo; E A Takano; H Thorne; S B Fox
Journal:  Br J Cancer       Date:  2009-09-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.